The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2024Chronos-PD Pilot: Analyzing Plasma from Donors Who Develop Parkinson’s Disease Later in Life
Study Rationale: Our current molecular understanding of Parkinson’s disease (PD) is based on the clinical phase of the disease. However, because PD is a progressive disease, by the time the disorder...
-
Research Grant, 2024Developing a Binding Assay to Detect Toxic Alpha-synuclein Aggregates in Cerebrospinal Fluid and Plasma
Study Rationale: The formation of toxic protein aggregates is an early step in the pathology of several neurodegenerative disorders, including Parkinson’s disease (PD). Using computer simulations, we...
-
Research Grant, 2024(SUPPLEMENT) Investigation of Small Molecules for Rescuing Lysosomal and GBA1 Deficiencies in GBA-associated Parkinson’s Disease
Study Rationale: Individuals with mutations in the GBA1 gene encoding the enzyme β-glucocerebrosidase (GCase) have a higher risk of Parkinson’s disease (PD). Gaucher disease, a rare genetic disease...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2024Interrogating Novel Defects in Protein Glycosylation in GBA1-associated Parkinson’s Disease
Study Rationale: Sugars are added to proteins in a process called glycosylation. The precise manner in which these sugars are added is critical for the proper function of the resulting glycoproteins...
-
Alpha-synuclein Seed Amplification Assay Program, 2024Maximizing Sensitivity of Alpha-synuclein Seed Amplification Assays by Eliminating Spontaneous Aggregation
Study Rationale: A key characteristic of Parkinson’s disease (PD) is the formation of alpha-synuclein aggregates in the brain. The ability to detect these aggregates in body fluids is important for...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Assessing the Safety and Efficacy of a Novel Enzyme Inhibitor in Reducing Neuroinflammation and Enhancing Neuroprotection in Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is characterized by neuroinflammation and the loss of dopamine neurons. Recently, epoxy-fatty acids have been shown to be neuroprotective in preclinical...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.